Altered progranulin levels play a major role in neurodegenerative diseases, like Alzheimer's dementia (AD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), even in the absence of GRN mutations. Increasing progranulin levels could hereby provide a novel treatment strategy. However, knowledge on progranulin regulation in neurodegenerative diseases remains limited. We here demonstrate that cerebrospinal fluid progranulin levels do not correlate with its serum levels in AD, FTD and ALS, indicating a differential regulation of its central and peripheral levels in neurodegeneration. Blood progranulin levels thus do not reliably predict central nervous progranulin levels and their response to future progranulin-increasing therapeutics.
CITATION STYLE
Wilke, C., Gillardon, F., Deuschle, C., Dubois, E., A. Hobert, M., Müller vom Hagen, J., … Synofzik, M. (2016). Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. Current Alzheimer Research, 13(6), 654–662. https://doi.org/10.2174/1567205013666160314151247
Mendeley helps you to discover research relevant for your work.